6 results
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
in HIV-AIDS Oropharyngeal ... Prevention #Treatment #management ... #opportunistic ... #infections #HIVAIDS ... #pharmacology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Diabetes #Mellitus #DM2 ... #Inpatient #Medications ... #pharmacology # ... comparison #table ... #endocrinology
IDSA Recommendations for Preventing and Treating Histoplasma Capsulatum Infections in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
in HIV-AIDS Indications ... with ARV (see Table ... Prevention #Treatment #management ... #opportunistic ... #pharmacology
Preoperative Risk Evaluation

Major Pre-Op Questions:
1. Does the patient have any modifiable risk factors that could be
- Allergies to medications ... Assess functional ... Skin exam for infection ... Insulin dependent DM ... medical and surgical management
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
prevent TB disease) Indications ... Please refer to the table ... Prevention #Treatment #management ... #opportunistic ... #pharmacology
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
Avium Complex in HIV-AIDS ... please refer to Table ... #opportunistic ... #infections #HIVAIDS ... #pharmacology